Showing results (1-10 of 27) with videos related to
Sort By:
Pageof 3
Acta Dermato-Venereologica|July 7, 2017
The AGEs of Psoriasis: A Biomarker for Severity and a Pathogenetic Link to ComorbiditiesLluís Puig, Anna López-FerrerExpert Opinion on Biological Therapy|June 26, 2019
Biosimilars for the treatment of psoriasisLluís Puig, Anna López-FerrerGlycoconjugate Journal|March 26, 2003
The expression of human FUT1 in HT-29/M3 colon cancer cells instructs the glycosylation of MUC1 and MUC5AC apomucinsAnna López-Ferrer, Carme de BolósExpert Review of Clinical Immunology|October 3, 2015
Secukinumab (AIN457) for the treatment of psoriasisAnna López-Ferrer, Eva Vilarrasa, Lluís PuigAmerican Journal of Clinical Pathology|November 14, 2002
Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinomaAnna López-Ferrer, Carlos Barranco, Carme de BolósDermatology and Therapy|February 2, 2026
Management of Obesity in Psoriasis ConsultationsJoana Nicolau, Anna López-Ferrer, Pablo de la CuevaDermatology (Basel, Switzerland)|August 15, 2012
Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and reviewLluís Puig, Caridad E Morales-Múnera, Anna López-Ferrer, et al.Patient Preference and Adherence|July 6, 2023
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and PerspectivesGemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer, et al.Cancer Science|April 27, 2007
Changes in the invasive and metastatic capacities of HT-29/M3 cells induced by the expression of fucosyltransferase 1Raquel Mejías-Luque, Anna López-Ferrer, Marta Garrido, et al.Pageof 3